Vivos Therapeutics, Inc. (VVOS) income statement
VVOSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 3/30
$0.08−0.00 (-4.64%)
Close on Nov 18, 2026Market cap $1.53MP/E –Yield –
Vivos Therapeutics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 61.9%
- Operating margin
- -107.9%
- Net margin
- -121.8%
- Return on equity, FY2025
- -655.0%
Financial strength
- Current ratio
- 0.21
- Debt to equity
- -2.13
- Debt to assets
- 33.7%
- Cash to current liabilities
- 8.7%
Valuation
- P/E ratio
- –
- Price to sales
- 0.07
- Price to book
- –
- Dividend yield
- –
See a number that looks wrong?